F008 Managing Tough Real Life Dermatology Cases
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
A faculty of experienced clinicians will present tough-to-manage real life patients, and how each was handled. The faculty is asked to focus on conditions that present to clinicians in private practice, and cases will span medical, surgical, and pediatric dermatology-- there will be something for everyone. We use an audience response system and encourage interaction between the audience and faculty. This activity has been approved by the American Board of Dermatology (ABD) for up to 20 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Recognize key diagnostic features of challenging disorders.
Manage tough-to-treat disorders.
Consider alternative treatment modalities.
SPEAKERS
Jeffrey Phillip Callen, MD, FAAD
Dirk Michael Elston, MD, FAAD
Anthony Fernandez, MD, FAAD
Andrea Maderal, MD, FAAD
Melissa Piliang, MD, FAAD
Samantha A Polly, MD, FAAD
Christine Baran Warren, MS, MD, FAAD
SPEAKER DISCLOSURES
Jeffrey Phillip Callen, MD, FAAD
3M Pharmaceuticals – Stockholder Public Company(No Compensation Received); Abbott Laboratories – Stockholder Public Company(No Compensation Received); AbbVie – Stockholder Public Company(No Compensation Received); Allergan, Inc – Stockholder Public Company(No Compensation Received); Amgen – Stockholder Public Company(No Compensation Received); Biogen – Data Safety Monitoring Board(Honoraria); Celgene – Stockholder Public Company(No Compensation Received); Elsevier Inc. – Other(Other Financial Benefit); EMD Serono – Other(Honoraria); JAMA – Other(No Compensation Received); Johnson and Johnson – Stockholder Public Company(No Compensation Received); Merck & Co., Inc – Stockholder Public Company(No Compensation Received); Pfizer Inc. – Stockholder Public Company(No Compensation Received); Procter & Gamble Company – Stockholder Public Company(No Compensation Received); Proivant – Data Safety Monitoring Board(Fees); UpToDate, Inc. – Other(Honoraria);
Dirk Michael Elston, MD, FAAD
No financial relationships exist with ineligible companies.
Anthony Fernandez, MD, FAAD
AbbVie – Consultant(Honoraria), Speaker(Honoraria); Biogen – Consultant(Honoraria); BMS – Speaker(Honoraria); Corbus Pharmaceuticals – Investigator(Grants/Research Funding); Kyowa Kirin – Speaker(Honoraria); Mallinckrodt Pharmaceuticals – Investigator(Grants/Research Funding), Speaker(Honoraria); Novartis Pharmaceuticals Corp. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Priovant – Investigator(Grants/Research Funding); UCB – Consultant(Honoraria);
Andrea Maderal, MD, FAAD
argenx – Consultant (1099 relationship)(Fees); aTyr Pharma – Investigator(Other Financial Benefit); Biogen – Investigator(Other Financial Benefit); Bristol Myers Squibb – Investigator(Other Financial Benefit);
Melissa Piliang, MD, FAAD
Eli Lilly and Company – Investigator(No Compensation Received), Speaker(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Investigator(No Compensation Received); Procter & Gamble Company – Consultant(Honoraria);
Samantha A Polly, MD, FAAD
No financial relationships exist with ineligible companies.
Christine Baran Warren, MS, MD, FAAD
UpToDate, Inc – Other(Patent royalties or other compensation for Intellectual Property Rights);